ArticleCritical care (London, England)2026
Analytical performance of species-targeted quantitative PCR for intra-abdominal candidiasis in critically ill patients: a proof-of-concept post hoc analysis from the pBDG2 multicenter study.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntra-abdominal candidiasis (IAC) is a severe form of invasive candidiasis that affects critically ill patients and is associated with a high mortality rate and persistent diagnostic delays. Conventional fungal culture from peritoneal fluid remains slow and has insufficient sensitivity. Molecular assays promote early diagnosis, but data from critically ill populations remain scarce.
objectivesWe evaluated the diagnostic performance of the OLM CandID Real-Time PCR assay directly applied to peritoneal fluid samples obtained from a previously established multicenter cohort of critically ill patients with suspected or confirmed IAC.
methodsOLM CandID Real-Time PCR is a quantitative PCR assay for detecting C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, and C. dubliniensis. Binary PCR results were compared with those of fungal culture as the reference standard. Secondary analyses analyzed quantitative PCR values to better understand culture-negative/PCR-positive discordances using ROC-derived cycle threshold (Ct) cutoffs.
resultsFifty-seven patients, mainly with postoperative peritonitis, were included. Among the culture-positive samples, C. albicans was predominant. Using binary interpretation, the PCR achieved 100% sensitivity (95% CI 100–100) and 60% specificity (95% CI 38–81); the positive and negative predictive values were 82% (95% CI 71–93) and 100% (95% CI 100–100), respectively. In the secondary Ct-based analysis, ROC-derived threshold determination was feasible for C. albicans (n = 35) and C. tropicalis (n = 12). For C. albicans and C. tropicalis, the ROC AUC values were 0.92 (95% CI 0.75-1) and 0.90 (95% CI 0.66-1), respectively, and applying the optimal Ct cutoffs (30.75 and 34.63 respectively) yielded 100% specificity and 100% positive predictive value for both species.
conclusionsOLM CandID Real-Time PCR applied directly to peritoneal fluid demonstrated strong analytical performance for the detection of Candida in critically ill patients with suspected IAC. The assay showed high concordance with culture results, supporting its feasibility for rapid microbiological assessment. Discordant PCR-positive/culture-negative results were mainly associated with high Ct values, likely reflecting low fungal burden, detection of non-viable DNA, or analytical over-detection. These findings are exploratory and highlight the need for prospective studies to determine the clinical relevance of quantitative PCR results and their role in guiding antifungal management.
trial registrationThe study was registered with ClinicalTrials.gov (ID number 07005258, first registered on March 6, 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.